Review

Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer’s Disease Neuropathology

Frédérique K. Kok¹, Suzanne L. van Leerdam¹ and Elizabeth C.M. de Lange*

Predictive Pharmacology, Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands

Handling Associate Editor: Giulio Taglialetela

Accepted 14 February 2022
Pre-press 7 March 2022

Abstract. Alzheimer’s disease (AD) is the most common form of dementia and typically characterized by the accumulation of amyloid-β plaques and tau tangles. Intriguingly, there also exists a group of elderly which do not develop dementia during their life, despite the AD neuropathology, the so-called non-demented individuals with AD neuropathology (NDAN). In this review, we provide extensive background on AD pathology and normal aging and discuss potential mechanisms that enable these NDAN individuals to remain cognitively intact. Studies presented in this review show that NDAN subjects are generally higher educated and have a larger cognitive reserve. Furthermore, enhanced neural hypertrophy could compensate for hippocampal and cingulate neural atrophy in NDAN individuals. On a cellular level, these individuals show increased levels of neural stem cells and ‘von Economo neurons’. Furthermore, in NDAN brains, binding of Aβ oligomers to synapses is prevented, resulting in decreased glial activation and reduced neuroinflammation. Overall, the evidence stated here strengthens the idea that some individuals are more resistant to AD pathology, or at least show an elongation of the asymptomatic state of the disease compared to others. Insights into the mechanisms underlying this resistance could provide new insight in understanding normal aging and AD itself. Further research should focus on factors and mechanisms that govern the NDAN cognitive resilience in order to find clues on novel biomarkers, targets, and better treatments of AD.

Keywords: Alzheimer’s disease, asymptomatic AD, non-demented individuals with AD neuropathology, preclinical AD, resilience

INTRODUCTION

In the pathology of Alzheimer’s disease (AD), two pivotal key hallmarks have been known and described for decades: amyloid-beta (Aβ) senile plaques and hyperphosphorylated tau proteins that form neurofibrillary tangles (NFT) [1]. Extensive research has shown that abnormal deposition of Aβ plaques and NFTs leads to synaptic damage and eventually to...
progressive cognitive impairment (e.g., memory loss), associated with dementia [2–5]. So far, drug development has been mainly focused on agents decelerating or preventing the progression of AD; however, most anti-AD therapies have been unsuccessful [6] and many promising findings in AD mouse models failed in translation to the clinical situation [7]. More recently, research is focused on identifying novel biomarkers and developing methods for early detection of AD. Currently, suggested AD biomarkers in the cerebrospinal fluid (CSF) are Aβ42; the Aβ42/40 ratio; phosphorylated tau at threonine residue 181 (pTau181) and tau protein [8].

Intriguingly, a multiplicity of literature originating from a variety of locations of the world has emerged that offers contradicting, yet intriguing, findings on the Aβ- and tau-hypotheses, as these histopathologic changes associated with AD have also been discovered post-mortem in non-demented older individuals. This suggests the existence of a group of non-demented, cognitively normal individuals carrying AD neuropathology.

In different recent studies, several synonyms (Table 1) have been used to describe these non-demented individuals, including but not limited to, non-demented individuals with AD neuropathology (NDAN) [9, 10]; non-demented high potential controls [11]; asymptomatic persons with AD neuropathology [12]; intermediate and high probability mismatches [13]; SuperAgers [14–16]; and asymptomatic AD (ASYMAD) [17–20]. All these studies have investigated older adults (65+ of age) with Aβ- and/or tau-deposition in absence of cognitive decline, dementia (Table 1). In this review, NDAN is defined as individuals that do not show the typical clinical-pathological correlation associated with AD, in other words individuals that carry AD pathology, as assessed post-mortem, but who despite this pathological burden performed cognitive normal antemortem.

Important to note is that, in general, normal aging elderly show some degree of AD pathology and of cognitive deterioration, but not to the extent that they identify as ‘NDAN’ or become demented. Looking at the Gaussian distribution of the association between AD pathology and cognitive impairment on a population scale, these individuals are located on the tail of the Gaussian, as they are relatively rare, with for instance 6 to 15 out of over 3200 volunteers in the Baltimore Longitudinal Study of Aging (BLSA) study [17, 21, 22]. But even though they might be exceptions to the average disease progression, at the same time, this makes them even more interesting to study in the search for a better drug target and treatment for AD.

Table 1: Studies that described non-demented individuals with AD neuropathology (NDAN), using different synonyms. These studies all focus on non-demented individuals with AD neuropathology or preclinical AD, studying brain tissue and/or data on cognitive performance. Cognitive assessment and AD pathology scores are specified in Tables 2 and 3, respectively

| Synonyms of NDAN                                      | Cohort study/Data set                                                                 | Reference
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-demented individuals with Alzheimer’s Neuropathology (NDAN)</td>
<td>Oregon Brain Bank at Oregon Health and Science University</td>
<td>[9, 10, 223]</td>
</tr>
<tr>
<td>Nondemented high potential controls (ND-HPC)</td>
<td>Banner-Sun Health Research Institute: Brain and Body Donation Program</td>
<td>[11]</td>
</tr>
<tr>
<td>Asymptomatic person with AD neuropathology</td>
<td>National Alzheimer’s Coordinating Center: Uniform Data Set and Neuropathology Data Set</td>
<td>[12]</td>
</tr>
<tr>
<td>Intermediate probability mismatches</td>
<td>Massachusetts General Hospital, Mayo Clinic and University of Pittsburgh ADRC Brain Banks</td>
<td>[13, 178]</td>
</tr>
<tr>
<td>‘Asymptomatic AD’ (ASYMAD)</td>
<td>The Nun Study/Baltimore Longitudinal Study of Aging (BLSA)/Medical Research Council London Neurodegenerative Diseases Brain Bank (INSIGHT) – preAD study</td>
<td>[17–20, 179]</td>
</tr>
<tr>
<td>Amyloid-PET positive subjective memory complaint seniors (SMCpos)</td>
<td>INveStIGation of AlzHeimer’s PredicTors Dementia of Alzheimer type</td>
<td>[61, 172, 173, 242]</td>
</tr>
<tr>
<td>Presymptomatic or incipient AD</td>
<td>–</td>
<td>[63]</td>
</tr>
<tr>
<td>Preclinical AD</td>
<td>–</td>
<td>[64]</td>
</tr>
<tr>
<td>Pathologically preclinical AD</td>
<td>–</td>
<td>[79]</td>
</tr>
<tr>
<td>SuperAgers</td>
<td>Australian Imaging, Biomarkers and Alzheimer’s Disease Neuroimaging Initiative (ADNI)</td>
<td>[170, 176, 177]</td>
</tr>
<tr>
<td>– 80+-year-olds, protected from Aβ neurodegeneration</td>
<td>–</td>
<td>[174, 175]</td>
</tr>
</tbody>
</table>
To disentangle NDAN from normal aging and AD, different mechanisms have been studied as summarized in Figs. 1 and 2. While some studies suggest that this asymptomatic form of AD is caused by resilience or resistance for Aβ toxicity, others focus on alternative potential mechanisms, such as the status of the risk gene for the apolipoprotein E (APOE), the immune system or neurogenesis. This review provides an overview on literature that focusses on NDAN, referring to all asymptomatic individuals with Aβ- and tau-pathology (Table 1), thereby aiming to provide more insight into potential mechanisms underlying AD pathology in absence of neurodegeneration and cognitive decline. Mechanisms underlying NDAN will also be compared to those underlying “normal” aging and AD in Fig. 2.

Fig. 1. Mechanisms in NDAN and AD brain. Top left: Increase of (re)active microglia and astrocytes accompanied with elevated levels of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) in AD. In NDAN brain glial activation is decreased and anti-inflammatory cytokine (IL-4, IL-10) levels are increased. Top right: In AD, proliferation of neural stem cells (NSCs) is decreased and ‘von Economo neurons’ (VENs) are degenerated, while in NDAN NSC proliferation is increased as well as VEN density. Bottom left: Volume of the hippocampus and corpus collosum is increased in NDAN. Bottom right: In AD, Aβ oligomers are able to bind the postsynaptic membrane and induce synaptotoxicity. In NDAN, binding of Aβ oligomers is prevented.

PHYSIOLOGY OF THE AGING BRAIN

Normal aging

An important characteristic of AD is cognitive decline, i.e., reduction of memory, attention, processing speed, visuospatial abilities, and executive functions. However, some degree of cognitive decline has also been associated with “normal” aging, as older individuals are often less efficient in cognitive tasks than younger people [23], but, which in general, does not convert into dementia [24]. To gain a better understanding in the process of normal aging, researchers from the Gerontology Branch at the National Institution of Health (NIH) launched the BLSA-study [22]. By following over 3,200
Fig. 2. Mechanisms in “normal” aging, AD and NDAN. Organ level: Shrinkage of grey matter in frontal and parietal volume over time in normal aging. Overall grey matter volume shrinks in AD but increases in NDAN brain. In NDAN the cingulate gyrus is thicker, and the hippocampus is spared, or increased in some cases. Neurons: Neurogenesis is decreased, and brain plasticity is increased in normal aging. In AD, NSCs proliferate less in the subventricular zone and hippocampus and VEN cells degenerate. NSC proliferation in the hippocampus of NDAN brain is increased, as well as VEN density. Inflammation: Microglia and astrocyte response to pro-inflammatory cytokines (IL-1, IL-6, and TNF-α) is increased in normal aging hippocampus. Microglia and astrocytes become more (re)active in AD, due to increased levels of pro-inflammatory cytokines (IL-1, IL-6, and TNF-α). Glial activation is decreased in superior temporal sulcus of NDAN, as anti-inflammatory cytokines (IL-4 and IL-10) are increased. Aβ: The molecular composition of Aβ molecules in normal aging is different than in AD and not distributed to specific areas. In AD, Aβ oligomers bind to synapses and induce synaptotoxicity. In NDAN, postsynaptic binding of Aβ oligomers is prevented by neuromodulators (Zn²⁺ [230] and Reelin [232]), Insulin [235] and specific APP miRNAs [182]. Tau: NFT distribution in normal aging is restricted to specific areas: entorhinal cortex, olfactory nucleus, and parahippocampal gyrus [49]. NFT levels in these areas are elevated in AD and also spread to the neocortex. In NDAN, NFT formation is inhibited in the temporal cortex, due to lower 0N3R expression [236]. A proposed mechanism for NDAN is to investigate the composition and location of different tau species.
volunteers for more than 60 years, this study shed light on the relationship between aging and cognitive health by looking at occurring changes in brain tissue and cognition over time. Both healthy and demented older volunteers appeared to lose a significant amount of both grey and white matter [25]. In the case of grey matter atrophy, especially the frontal and parietal volume declined over time. And both the ventricles in the brain as well as the volume of ventricular CSF increased over time [25]. These findings suggest that both atrophy and increased ventricles reflect normal aging. However, these physiological changes are brain region dependent, e.g., the mesial temporal and frontal areas are more susceptible to AD pathology, rather than to normal aging [25].

The brain atrophy as seen in the aging brain could either result from neurodegeneration or from alternations in neurogenesis. Neurogenesis (or gliogenesis) is responsible for the production of new brain cells, such as neurons and the glial cells like astrocytes, oligodendrocytes, and ependymal cells [26]. In contrast to neurons which conduct action potentials, glial cells do not, but instead maintain homeostasis, and protect and support neurons. An important type of glial cell involved in the pathology of AD are microglia [27–30]. Unlike other glial cells, microglia do not derive from neurogenesis, but from hematopoietic stem cells [31, 32]. Microglia play an important role in neuroinflammation, functioning as resident macrophages of the central nervous system. In order to understand normal physiological changes during aging, Mayne et al. (2020) discussed functional decline of the adaptive immune system in healthy aging in comparison to several neurodegenerative diseases [33]. They illustrate that the response of microglia and astrocytes to pro-inflammatory cytokines was increased in brains of aging mice indicating higher sensitivity to inflammatory events [33, 34]. Furthermore, the increased secretion of interferon-γ by cytotoxic CD8$^+$ T cells led to decreased neurogenesis in the hippocampus [33, 35]. Overall, their findings clearly indicated a role of the immune system in the reduction in neurogenesis in the aging brain. In addition to T-cells, natural killer cells have been implicated in impaired neurogenesis [35, 36], as well as oxidative stress and impaired DNA repair [37]. Interestingly, while neurogenesis can be reduced due to aging, the brain’s plasticity was found to be enhanced, yet dysregulated in aged rats [38].

Another feature of “normal” aging is the presence of NFT and Aβ, as found in brains of cognitively normal elderly [39, 40–44]. In “normal” cellular metabolism, the enzymes β- and γ-secretase are responsible for cleavage of the amyloid-β protein precursor (AβPP), yielding Aβ peptides [45]. Aβ peptides can aggregate to form soluble oligomers and insoluble fibrils and plaques (Fig. 3). Perhaps counter intuitively, not the insoluble but the soluble oligomeric Aβ cause more neural damage as it binds easier to synapses, as has been proven extensively [46]. Normal Aβ production and degradation is balanced out by proteolytic degradation, deposition into insoluble plaques and cell-mediated clearance [45]. Tau is “normally” present in the aging brain as a highly soluble protein that primarily maintains microtubules in axons [47]. When tau proteins become hyperphosphorylated, it aggregates and NFTs are formed. As deposition of NFT and Aβ are both associated with AD patients and “normal” aging, an important question is if these NDAN individuals are resilient to tau- and Aβ-pathology. In experiments with virally induced human tau in entorhinal cortex neurons of young and old mice, it was shown that tau

![Fig. 3. Aggregation of Aβ, from monomers to plaques. Soluble Aβ monomers aggregate together to form dimers and oligomers, that can form soluble protofibrils. These protofibrils aggregate to form insoluble fibrils, that can form amyloid plaques.](image-url)
spreading was not only age- but also region dependent [48]. More specifically, the human tau expanded from the entorhinal cortex, to the hippocampus and the temporal lobe in old mice. In line with these findings in mice, it was found that NFTs can be distributed to the entorhinal cortex, olfactory nucleus and the parahippocampal gyrus in non-demented aging humans [49]. In mildly demented cases, distribution was similar to non-demented cases, but much more tangles were found in these areas. Only in the severely demented cases, NFTs were found also in the neocortex [49]. Conversely to NFT, consistency in the distribution of Aβ in “normal” aging has not been found yet. In 2005, Piccini et al. did hypothesize that the molecular composition of soluble Aβ aggregates could differ between “normal” aging and AD [50].

MECHANISMS UNDERLYING ALZHEIMER’S DISEASE

AD can be heritable, attributed to mutations in the potential genes that encode for amyloid precursor protein (APP) and presenilins (PSEN) 1 and 2 [51]. Mutations in one of these genes result in increased production of the protein Aβ42. In contrast to the heritable familiar AD cases, in the sporadic AD cases, risk factors consist more of environmental and as well as genetic factors. One well known genetic risk factor is the APOE allele e4, which increases the risk of AD but is not determinative for the disease [52, 53].

Under healthy conditions, ApoE enhances binding to, transportation of, and metabolism of lipids. However, in AD pathology, ApoE binds additionally to Aβ peptides and also regulates Aβ aggregation and clearance [54]. Moreover, the ApoE lipoproteins regulate neuronal signaling, glucose metabolism, and neuroinflammation, all mechanisms implicated with AD, as will be discussed further in this review. Another important causative factor in the pathology of AD is the protein tau. Hyperphosphorylation of tau protein results in the formation of NFTs [55]. Together with Aβ pathology, NFTs are defined as the typical hallmarks of AD.

AD on a body level

Looking at AD on a body level, studies have been focusing on multiple risk factors that are able to modify the onset and the rate of decline seen in AD. Investigated risk factors include age, gender, education, neuropathology, personality, genetics, lifestyle, and cognitive functioning [56–60].

AD symptoms in patients mostly consist of cognitive and functional impairment—dementia. The progressive course of AD is divided in several stages [23]. The first stage, preclinical AD stage, was initially defined as cognitively unimpaired individuals, who contained AD lesions in their brain as identified postmortem [61]. During this stage, clinical symptoms are not yet noticeable [62]. Since individuals in the preclinical stages and NDAN individuals both display AD neuropathology in the brain, but symptoms are not (yet) evident, this preclinical stage provides an interesting perspective for NDAN research [63, 64]. The first clinical stage of cognitive decline starts with subjective cognitive decline (SCD), defined as a very early and subtle cognitive decline which precedes objective cognitive decline [65]. The second stage is called the mild cognitive impairment (MCI) stage [66]. This MCI stage lays between expected cognitive decline associated with normal aging and more severe decline associated with dementia. This MCI stage is marked by symptoms of short term memory loss, especially in retrieving learned facts, and inability to acquire new information [67]. Moreover, deficits occur in planning, executive functions, attentiveness, and impairments in semantic memory (refer to general knowledge). All these MCI symptoms are hard to distinguish from normal aging and can improve over time, remain stable for years, or progress to AD or another type of dementia. During the SCD and MCI stages, diagnoses of patients is difficult, since these first symptoms of AD are hard to distinguish from normal aging. In later stages, the final stage of AD, memory problems become overshadowed by new difficulties: aphasia (difficulty communicating), agnosia (difficulty processing sensory information), and apraxia (inability in executing motor tasks) [68, 69]. During this final AD stage of the disease, it becomes more difficult for patients to execute tasks and therefore, most AD patients eventually need assistance.

To provide good care and disease intervention, a correct diagnosis of the disease is necessary. The current standard to diagnose AD is based on the definition of the Diagnostic and Statistical Manual (DSM)-IIIR for dementia and AD criteria and the diagnostic guidelines from the National Institute on Aging-Alzheimer’s Association (NIA-AA) [70]. This diagnostic method is based on medical history and cognitive testing after ruling out other possible causes. Over the years, these criteria have been
specified further to improved accuracy, using imaging and blood tests [62, 66, 71]. Nevertheless, postmortem confirmation of the AD hallmarks is still required for a definitive diagnosis of AD.

With respect to postmortem confirmation, several methods can be used to verify and classify AD. Traditionally, NFT pathology has been assessed using Braak staging system [72, 73] (Fig. 4). The Braak staging system is used to classify the morphological changes that occur over time in AD patients. For long, this system has been used to predict AD, as the latter Braak stages typically indicate a clinical outcome of dementia, even though the system was not developed for clinical-pathological correlation. Nelson et al. (2012) reviewed the validity of the clinical-pathological correlation in AD thereby focusing on neuropathological (Aβ and tau) changes and cognitive impairment using Mini-Mental State Examination (MMSE) scores [74]. The authors state that the cognitive impairment in AD correlates better with neocortical NFT pathology than with Aβ plaque. However, NFT pathology also occurs in normal aging, as described in the previous section. For this reason, it could be questioned if Braak staging provides a valid prediction for AD, and also for NDAN [75, 76]. Especially during the slow-developing pathology of AD, morphological changes in the brain do not always directly translate into behavioral differences. However, at this point the question remains, is this a defect in the pathological evaluation itself, and can Braak staging be used to evaluate AD and NDAN, or is there something else missing? Another neuropathological diagnostic criteria instrument is the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) which evaluates the density of neocortical senile plaques [77–79].

Altogether, the slow and gradual decline observed in AD ensures the challenges in treatment of this disease. The AD-associated processes will be discussed next on the organ levels, followed by the cellular and biochemical level to gain deeper understanding of AD, and for the ultimate comparison of AD patients and NDAN individuals.

**AD on an organ level**

AD is characterized by neurodegeneration in specific areas of the brain, causing the cognitive decline as described in the previous section. Typically, histological changes first appear in the limbic system, especially the hippocampus and entorhinal cortex [80]. In particular, atrophy in the CA1 region of the hippocampus is indicative of AD, not of aging [81, 82]. This suggests that memory loss in AD is enhanced by CA1 atrophy, resulting in a greater memory decline than observed in normal aging. After CA1 atrophy, the atrophy affects the temporal and frontal cortex, and parts of the cingulate gyrus and parietal lobe (reviewed in [83, 84]). As a result of this neuronal loss, the ventricular system extends. Meanwhile, the spinal cord and cerebellum seem to stay unaffected [80].
As described in the previous section, the post-mortem classification of AD is performed by the Braak staging system (Fig. 4), based on the characteristic distribution pattern of neurofibrillary changes throughout the brain [73]. Initially, the trans entorhinal to the hippocampal region become affected (Stage I & II), thereafter the temporal, frontal, and parietal neocortex (Stage III & IV), and eventually followed by alterations in the primary sensory and motor areas (Stage V & VI). The affected regions correlate with loss of recent memories (stages I-II), impairment of language and planning areas (stages III-IV), and finally malfunctioning of object recognition and motor skills (stages V-VI).

Several AD subtypes have been defined based on the atrophy pattern [85–89]. Ferreira et al. (2017) used magnetic resonance imaging (MRI) to predict and investigates three subtypes of AD: typical AD, limbic-predominant, and hippocampal-sparing forms of AD [89]. In typical AD brains, neurodegeneration appeared in the mesial temporal lobe and in the posterior cortex and/or frontal cortex. In contrast to the typical AD, the limbic-predominant subtype was defined as atrophy in the mesial temporal lobe only, whereas in the hippocampal-sparing AD subtype, this mesial temporal lobe was spared. The latter generally did not experience amnesia. Furthermore, another study identified a subtype of patients with neither hippocampal nor cortical atrophy [90]. This AD subtype did show cognitive impairment, despite their seemingly spared brain areas. This could be explained by possible limitations in the diagnostic accuracy guidelines from the NIA-AA or due to other factors that are not yet identified in the mechanism of AD.

Another aspect of AD is reduction of the cerebral blood flow (CBF). In AD, Aβ peptides indirectly can cause a reduction of CBF due to interference with nitric oxide-mediated vasodilation [91]. Reduction of CBF results in impaired supply of glucose, nutrients, and oxygen, and diminished elimination of toxic products. Therefore, reduction of CBF contributes to neuronal damage. In parallel, Aβ induces reactive oxygen species that activate the release of endothelin-1, which in their turn elicits constriction of pericytes which results in capillary constriction and reduced CBF [92]. Particularly, regional CBF (rCBF) reduction is one of the earlier markers for dysfunction in specific areas associated with AD [93]. This rCBF reduction follows the same trend as the observed areas affected in AD pathology: the posterior cingulate, precuneus, and mesial temporal lobes. However, rCBF is further reduced in AD patients, namely in the hippocampus, caudate, and thalamus [94]. For this reason, measuring the CBF in these regions, using MRI or positron emission tomography (PET), is a useful method to predict cognitive decline [95, 96].

**AD on a cellular level**

During AD, neurons and synapses lose their structure and function, and eventually die, resulting in atrophy as described above. Altogether this is referred to as neurodegeneration, hence AD is a neurodegenerative disease. Neurodegeneration as observed in AD results from to neurotoxic tau and Aβ, together with aging and inflammation [97].

To get a better idea of neurodegeneration, it is important to not only investigate neuronal death but also neuronal production. Neurons themselves do not proliferate in adult life, however, new neurons can be derived from neuronal stem cells (NSC) by the process of neurogenesis [26]. Adult neurogenesis has been observed in two regions of the brain, namely the mature subventricular zone of the lateral ventricles and the dentate gyrus part of the hippocampus [98, 99]. As indicated previously, mild memory loss is associated with “normal” aging, which could be the result of region-specific neuronal alterations caused by brain plasticity [100] (Fig. 2). Alternatively, neurogenesis in the hippocampus declines with age and therefore causes potential complications in memory function [101]. In AD, neurogenesis is impaired. Studies in AD mice revealed that NSCs in the adult subventricular zone proliferate less and fail to differentiate into healthy mature neurons [102]. Scopa et al. (2020) concluded that neurogenesis in this zone was already impaired in the early stages of AD, due to Aβ oligomers in the endoplasmic reticulum of NSCs. For many years, researchers speculated that AD pathology affected neurogenesis and that neurogenetic misfunction correlated with neuronal loss as seen in AD [103–105]. More recent attention has focused on the groundwork of adult hippocampal neurogenesis in over 90-year-old individuals with MCI and AD [106, 107]. Specifically, MCI patients showed reduced numbers of neuroblasts, premature neurons originating from NSCs [107, 108]. This data suggests that neurogenesis may already decline during MCI. In line with this finding, it is not surprising that adult neurogenesis in the human hippocampus was found to be impaired already in the early stages of AD pathology [109].

In addition to the two hallmarks of AD (Aβ plaques and NFT), neuroinflammation is considered to be the
next most important contributor to the progression of AD. Over the last decade, the importance of this process has emerged more and more and in 2020, the link between neuroinflammation and AD has been elaborately discussed in reviews [110, 111]. Neuroinflammation in AD has been observed in human brain tissue and on a molecular imaging level [112–115]. More specifically, on the one hand, astrocytes become more reactive in response to Aβ, releasing pro-inflammatory cytokines [116, 117]. On the other hand, there is increased interest in the brains-resident immune cell, the microglia. As explained earlier, these particular glial cells are the resident immune cells of the brain, that can phagocytose pathogens and display antigens to activate T-lymphocytes [30]. In AD, microglia play a major role in endocytosis and degradation of soluble and fibrillar Aβ species [29]. Initially, this process is beneficial to prevent Aβ accumulation, but as soon as the Aβ levels are chronically elevated, microglia activation will result in prolonged inflammation and enhances AD progression. The impact on AD progression is particularly influenced by the phenotype of microglia (M1 or M2) involved, as type M1 microglia enhance cellular immune responses while type M2 inhibit classic inflammation and promote wound healing [118, 119]. The mixed population of microglia results in a heterogenic neuroinflammatory response that influences AD progression and effectiveness of possible treatments, notably in adults with early AD [112].

Besides (re)active glial cells, several cytokines have been associated with AD. The deposition of Aβ activates astrocytes and microglia that trigger the secretion of several inflammatory cytokines. Firstly, interleukin (IL)-1 can increase AβPP synthesis and secretion, and subsequently generation of Aβ [120]. Furthermore, microglial production of IL-1 activates the p38 mitogen-activated protein kinase (p38-MAPK) pathway and thereby increases the phosphorylation of tau [121]. Secondly, elevated levels of IL-6 have been found in AD brains, which can increase the expression of AβPP as well [122]. Thirdly, IL-10 inhibits the macrophagic function of microglia and thereby indirectly decreases cerebral Aβ clearance [123]. Lastly, tumour necrosis factor (TNF)-α stimulates the activity of γ-secretase, resulting in an increased production of Aβ from AβPP [120]. Increased levels of this pro-inflammatory cytokine were also found in CSF and blood of MCI patients, who later progressed to AD [124]. Moreover, results from a cell culture study indicated that microglia, when activated by Aβ, release reactive oxygen species and also TNF-α, creating a positive feedback loop of enhanced Aβ and microglial induced inflammation [125]. Together, these cytokines affect the proliferation and survival of both neurons and NSCs and enhance the progression of AD. To conclude, these studies clearly indicate that there is a strong relationship between neuroinflammation and the progression of AD, which needs to be considered in the pathology of the disease.

In literature, many different theories of AD etiology have been proposed, including the vascular hypothesis that states a reduction in CBF [126]. The reduction in CBF may result from blood-brain barrier (BBB) dysfunction as indicated by recent studies [127–132], suggesting a potential causal relationship between AD and cardiovascular dysfunction. Under healthy conditions, the BBB protects the brain by preventing access for blood cells, pathogens, and neurotoxic components in the blood [133]. During the early stages of AD pathophysiology, breakdown and dysfunction of the BBB occurs. This BBB breakdown results in leakage throughout the cerebrum, due to dilatation of the BBB’s tight junctions [134]. The integrity of these tight junctions is, among others, regulated by APOE, which is, as mentioned above, an extensively investigated risk gene in AD research [135]. Additionally, another study showed that increased BBB permeability resulted from Aβ-induced pro-inflammatory and cytotoxic events [136]. Together, this indicates that AD is indirectly associated with increased BBB permeability. Furthermore, Montagne et al. (2015) observed a breakdown of the BBB in hippocampal areas, CA1, and dentate gyrus in healthy elderly [127]. These findings suggest that the breakdown of BBB contributes to the cognitive impaired symptoms that are associated with aging and AD.

In short, multiple processes in the brain are affected by AD pathology (Fig. 2). In AD, neurons degenerate, while the formation of new neurons is impaired at the same time. Moreover, astrocytes and microglia become reactive in the presence of Aβ, triggering the release of several pro-inflammatory cytokines. This cytokine release could be associated with the decline observed in BBB tight junction integrity, causing more neurotoxic components to enter the brain and inducing an immune response. Furthermore, CBF is reduced in AD brains, suggesting a decrease in blood supply and decreased synaptic activity. All these mechanisms can be caused by Aβ and NFT pathology of AD, which will be discussed next.
**AD on a biochemical level**

**Amyloid-β pathology**

The Aβ molecules exist of peptides derived from AβPP; an integral membrane protein expressed in synapses. It is thought that AβPP functions as a regulator of neural plasticity and synapse formation [137, 138]. Mouse studies suggested that AβPP plays an important factor in neurogenesis, as APP–/– mice showed no increase in neuronal proliferation and reduction in brain weight [139]. Nevertheless, AβPP itself is not responsible for the pathological development occurring in AD. When AβPP is cleaved by β- and γ-secretase, it generates Aβ peptides from different sizes [140–142]. These Aβ isoforms vary from 30 to 51 amino acid residues. The two most prevalent isoforms are Aβ40 and Aβ42, which are produced in both neuronal and nonneuronal cells. The ratio of Aβ42/40 is an important factor to determine fibrillation and consequent toxicity of Aβ [143]. Aβ40 is produced in the endoplasmic reticulum (ER) for Aβ42 is produced in the endoplasmic reticulum (ER) [144]. Especially, the ER-derived isoform, Aβ42, is notorious as it is best at misfolding and forming the toxic Aβ oligomers [145] and consequently, with a higher ratio of Aβ42/40 more toxic oligomers are formed. Neuronal cell culture studies demonstrated that Aβ oligomer exposure induced cell death, which was mediated by acute toxicity triggered by oxidative stress [146, 147].

Not only insoluble Aβ oligomers (which lead to plaque formation), but also soluble Aβ oligomers (Fig. 3) play an important role in the pathology of AD [148] and the presence of high Aβ oligomer levels in CSF of AD patients may indicate an increased risk of AD [149]. In another study, significantly higher levels of Aβ oligomers were found in CSF samples from AD patients compared to controls, as well as an elevated ratio of Aβ oligomers to Aβ42 [150], which, in Aβ(PP)-expressing cultured cell lines, were associated with loss of dendritic spines and loss of synaptic function [46]. This observation is crucial because Aβ oligomer-induced synaptic loss results in disruption of neuronal communication.

Shankar et al. (2008) also found that these Aβ oligomers were bound to the synapses and inhibited long-term potentiation, while enhancing long-term depression (LTD). Enhancing LTD in the hippocampus, together with the reduced dendritic spine density, eventually results in interruption of memory and learning ability. Furthermore, Shankar et al. (2008) illustrated the synaptotoxic role of Aβ dimers in this process, as Aβ dimers solubilize amyloid plaques and disrupt glutamatergic synaptic transmission that is necessary for LTD. It is believed that the misfolded Aβ fulfills a prion function: misfolded proteins that can convey their misfolded shape onto other proteins [151–153]. Not only Aβ, but also tau proteins can be misshaped as a result of these misfolded Aβ [154]. The toxic behavior of misfolding also perturbs when misfolded Aβ and tau enter neurons which contained properly folded and functioning Aβ and tau.

To detect Aβ plaques, a radioactive analogue of thioflavin T, Pittsburgh compound B (PiB) is used. This compound, 2-(4'-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C-PiB]), can bind to Aβ fibrils and is visible through PET imaging [155]. Binding of [11C-PiB] to Aβ enables us to diagnose AD pathology and investigate the areas that are affected by Aβ. Yet, Aβ pathology was not significantly associated with cognitive AD symptoms and had, therefore, no predictive advantage, while NFT does [156] (see below). This conclusion contradicts that of Pike et al. (2007) who found a strong correlation between impaired episodic memory and increased binding of PiB [157]. But, as impaired episodic memory is not the only symptom indicative for AD, this approach can be used to fulfill some of the antemortem detection of Aβ, but cannot assess the degree of cognitive impairment.

**Tau pathology**

The other hallmark of AD are tau proteins, which aggregates into NFTs. Under healthy conditions, tau proteins are highly soluble proteins with different isoforms produced by alternative splicing from the microtubule-associated protein tau (MAPT) gene [158] (Supplementary Figure 1). Primarily, the role of tau in the central nervous system is to stabilize the microtubules in axons; however, these proteins can also be expressed in non-neuronal cells, including astrocytes and oligodendrocytes [159]. Tau proteins can become phosphorylated by different protein kinases on various sites that regulate microtubule binding [160]. In total approximately 45 phosphorylation sites have been reported, either being tyrosine, threonine, or serine residues (Supplementary Figure 2). Phosphorylation of these different residues is regulated by different kinases including GSK-3, PKN, and CDK5 [161, 162]. Phosphorylation interferes with microtubule binding; consequently, the hyperphosphorylated state of tau decreases the
solubility of the protein, resulting in its aggregation into bundles of paired helical filaments, the NFTs [163]. During AD, this hyperphosphorylated, insoluble form can no longer bind and stabilize the microtubules, and therefore indirectly demolishes the microtubules, thereby weakening the cytoskeleton and obstructing axonal transport [161]. Inhibition of axonal transport can lead to oxidative stress in mitochondria and eventually cell death [164]. Moreover, tau’s indirect inhibition of axonal transport leads to the accumulation of AβPP, the precursor of the other AD hallmark (see the section on Amyloid-β pathology above). The quantity and distribution pattern of tau correlate with the degree of decreasing cognitive performance and memory in AD. Tau staining is performed using silver and immunohistochemical staining for hyperphosphorylated tau [72, 73]. As discussed previously (see the sections AD on a body & organ level above), the Braak staging system is based on the deposition of tau, the formation of NFT and neuropil threads in neurites [72, 73]. Apart from this system to identify AD stages, Braak et al. pointed out the importance of hyperphosphorylation of tau, as accumulation of tau already starts years before the first signs of AD occur. This highlights the importance of tau as a valuable hallmark for AD. However, NFT distribution was also seen in “normal” aging (Fig. 2); therefore, it is important to also investigate the distribution and composition of tau species in NDAN.

NON-DEMENTED INDIVIDUALS WITH AD NEUROPATHOLOGY

Until the past decade, researchers in the field of AD have been focusing on the link between the clinical symptoms of dementia and the two hallmarks: Aβ and tau. However, several longitudinal, cohort studies have been suggesting that it is not as straightforward as was anticipated. One review discussed demented patients, without amyloid or tau pathology, as well as cognitively intact individuals with severe AD pathology [165]. Nelson et al. (2009) illustrated that individuals without or with mild dementia tend to have less NFT counts in the neocortex, while when NFT counts are over a certain threshold, cognitive impairment is inescapable. Moreover, in cases with many NFT counts, the combined amount neuritic and diffuse amyloid plaques was increased. Therefore, Nelson et al. (2009) strongly agreed with the clinical-pathological correlation of NFT and neuritic and diffuse amyloid plaques to cognitive impairment. In 1958, the BLSA started investigating the normal progression of aging [22]. In this program, the presence of AD neuropathological changes was found in several of the autopsies of individuals that displayed normal, non-demented behavior prior to their death. Another longitudinal aging study, the Nun Study (1986), found that 12% of the cognitively intact participants showed abundant Aβ plaques and NFT during postmortem examination [166–168]. After the successful findings of the Nun Study, the Rush Religious Orders Study (1992) was executed [169]. The Rush Religious Orders researchers, Bennett and Schneider, found that one-third of older people’s brains had serious AD lesions, while these people were not cognitively impaired. Not only in America, but also in Australia an aging and AD study was launched in 2004: the Australian Imaging, Biomarker & Lifestyle Flagship (AIBL) Study [14, 170], and found a significant Aβ deposition in the brains of some non-demented individuals [171]. More recently, a group in Paris investigates the compensation mechanisms in individuals with AD lesions that maintain their cognitive capabilities. To aim this, the “INVeStIGation of AlzHeimer’s PredicTors” (INSIGHT-preAD) study was launched in 2013 and is still ongoing [172]. Within the INSIGHT-preAD cohort, positive amyloid deposition was found in asymptomatic individuals [173]. Taken together, these studies indicate the existence of a group of elderly that do not develop dementia during their life, despite the AD neuropathological burden in their brains. Therefore, it is thought that other factors, or maybe even an undetected hallmark in the pathology of AD, play an important role in altering the risk for AD or the progression of AD. So, what distinguishes NDAN individuals from normal AD patients and “normal” aging, and what key features are still missing?

As was pointed out in the introduction of this review, already many different studies have been performed regarding these NDAN cases (Table 1). Although a variety of synonyms have been used, some studies focus on a specific age interval and others investigated the preclinical state of the disease. Moreover, the conditions by which individuals are labeled as NDAN differ between studies. Nevertheless, all these studies have been investigating the potential missing link between the two hallmarks of AD and the cognitive outcome that is expected in this disease. Already at the end of the last century,
researchers tried to distinguish normal aging from the preclinical state of AD, in which the quantity of neuropathological changes has not yet affected cognitive behavior. Morris et al. (1996) discussed whether the cerebral deposition of Aβ in nondemented elderly indicated early AD in its presymptomatic phase or simply “normal” aging [63]. Moreover, Schmitt et al. (2000) referred to preclinical AD subjects as having AD-like changes, but exhibiting no cognitive differences [64]. Moreover, they suggested that the aging brain might cope with these changes and remain normal cognitive functioning. Both Morris et al. and Schmitt et al. refer to this phenomenon as the delay in time between the pathological progression and the expression of disease and symptoms. Later researchers started to use the term cognitive reserve (or buffer), in expectation that symptoms will eventually occur [174, 175]. Another synonym that is being used to describe NDAN specifically focuses on non-demented individuals within a certain age range. So did Maarouf et al. (2011) who described a group cognitively intact nonagenarians with high amyloid plaque loads and classified these as non-demented high pathology controls [11]. Similarly, the term ‘SuperAgers’ was used to refer to 80-year-old elderly, with a level of episodic memory that is equal or better than those between 50- to 60-year-old [14, 15, 176, 177]. Alternatively, the group of Gómez-Isla described these non-demented individuals with significant amounts of AD changes as high or intermediate probability mismatches or resilient to the AD pathology [13, 178]. Additionally, scientists even use different terms to refer to a non-symptomatic behavior of AD, dementia, observed in individuals with significant AD neuropathology. The group of Troncoso investigated asymptomatic AD (ASYMAD) in BLSA and conducted their research on a histological, proteomic, and transcriptomic level [21, 179, 180]. Lastly, the synonym that is used in this review, ‘NDAN’, was already described by Zolochevska and Taglialetela [9, 181, 182]. Altogether, these scientists have all contributed to unravel the underlying mechanisms that differentiate NDAN from normal aging and AD. Some of these studies mainly focused on delaying the effects of aging, as aging is an inevitable process that can be seen as a risk factor for AD. At the same time, delaying the effects of aging itself can provide useful insight into the resilience of AD. In this section, these potential mechanisms will be discussed on a body, organ, cellular, and biochemical level aiming to gain a bigger understanding of NDAN.

POTENTIAL MECHANISMS UNDERLYING NDAN

As mentioned earlier, already multiple risk factors for AD have been examined by previous researchers. These factors—age, gender, education, neuropathology, personality, genetics, lifestyle, and cognitive function—can modify the onset and rate of decline of AD and therefore also need to be considered in NDAN research [56]. Morphological changes of the brain and the neurons, inflammation, Aβ, and tau have already been discussed in the context of normal aging and AD (Fig. 2) and will here be discussed in the context of NDAN. First, NDAN is discussed on an organism level from an age, education, and cognitive perspective.

NDAN on a body level

Typically in AD, patients encounter dementia-like symptoms, including memory impairment, difficulties with language, and moving difficulties [183, 184]. Diagnostic classification of AD is initially executed using several cognitive performance tests on, for instance, memory recalling, perceptual speed, and verbal fluency. As explained earlier, pathological diagnoses and cognitive testing is needed to confirm the AD diagnosis, using Braak staging system, CERAD, and NIA-AA neuropathologic criteria for AD. These neuropathologic criteria have also been used to examine cognitive functioning in non-demented elderly [185]. The study by Bennett et al. (2006) found that some of these non-demented individuals were allocated with an intermediate or high likelihood to develop AD, a crucial discovery, as it demonstrates the heterogeneity in the extent to which AD pathology correlates with cognitive impairment.

Several studies performed among different populations worldwide have demonstrated Aβ aggregates and NFT in 20–40% of the cognitively intact elderly [63, 71, 186–190]. Specifically, the study performed by Driscoll et al. (2006) assessed cognitive performances of cognitively normal elderly controls, individuals with MCI or AD, and NDAN individuals over a time span of 16 years or longer [190]. These individuals underwent prospective neurological evaluations on several cognitive domains, including memory, visuospatial abilities, attention, and word knowledge, and eventually underwent autopsy. Interestingly, the authors found that the cognitive trajectories between cognitively normal older individuals and NDAN, declines similarly, whereas
the cognitive trajectories of individuals with AD or MCI showed an accelerated decline. Surprisingly, this accelerated decline could be observed already prior to the diagnosis of AD or MCI. In other studies, including the more recent study performed by Dang et al. (2019), the new term ‘SuperAgers’ was introduced which is defined as cognitively strong 80+-year-old NDAN that are resistant to neurodegeneration associated with age and Aβ [14]. In this study, SuperAgers were case-matched to cognitively normal individuals for their age, based on sex and education (control subjects) and their memory performance was investigated over a time span of 90 months. They found that SuperAgers had less Aβ-associated decline compared to control subjects. It can thus be suggested that these individuals are resilient to AD pathology.

Since the discovery of NDAN cases, an Alzheimer’s Association workgroup suggested alterations in the diagnostic guidelines of AD (part of the NIA-AA) which would allow for the separation of NDAN individuals from typical AD patients [71]. Consequently, many researchers started assessing the cognitive function of their subjects using the Clinical Dementia Rating (CDR) score and/or MMSE (Table 2) [191, 192]. Most of the cited studies summarized in Table 2 include only a small amount of individuals with an MMSE score > 27.5, except for the study on SuperAgers and amyloid-PET positive subjective memory complaint seniors (SMCpos) [16, 172], showing that inclusion criteria vary between studies and that the group of NDAN individuals is rare or at least difficult to recruit or study. Some scientists analyzed the clinical-pathological correlation by investigating the correlation between MMSE scores and Braak stages [193]. According to these authors, a “ultimate NDAN”, having a MMSE score of 30 and end-stage tau pathology combined in one individual, did not exist in their analyzed datasets of 3,310 cases. This outcome provides another prospective in the NDAN research. However, the research goal is not to find and then study the “ultimate NDAN”, but to gain insights in the missing link between the currently accepted AD pathology and the actual clinical AD outcome. To achieve this goal, the “ultimate NDAN” cannot and does not have to be the golden standard for NDAN. However, it remains debatable what would be the best cut-off point of the MMSE or CDR score to define individuals as cognitively intact, and should one take into account that an individual with a high score can still be cognitive impaired relative to their own baseline? And what is the threshold that states whether an individual has AD pathology?

Looking at scoring the cognitive functions of individuals, the CDR is used to distinguish three stages of dementia from healthy individuals, based on their performance in memory, orientation, problem-solving, community affairs, home and hobbies, and personal care [191]. Each category is scored independently as healthy (0), questionable dementia (0.5), mild dementia (1), moderate dementia (2), and severe dementia (3). Unfortunately, not all studies focused on NDAN cases included CDR scoring, but in the studies that did include CDR scores, almost all patients had low scores (between 0 and 0.5) indicating healthy or very questionable dementia (Table 2). The study of Upadhaya et al. (2014) had two

Table 2

<table>
<thead>
<tr>
<th>NDAN or Synonym</th>
<th>Number of participants</th>
<th>Age</th>
<th>CDR</th>
<th>MMSE</th>
<th>Time of last evaluation prior to death</th>
<th>References of performed studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDAN</td>
<td>N = 4</td>
<td>≥ 89</td>
<td>–</td>
<td>26–29</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>NDAN</td>
<td>N = 8</td>
<td>76–89</td>
<td>–</td>
<td>27–30</td>
<td>Several months</td>
<td>[10]</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>N = 82</td>
<td>81.3</td>
<td>0</td>
<td>29.23 ± 0.88</td>
<td>&lt; 1 year</td>
<td>[12]</td>
</tr>
<tr>
<td>SA</td>
<td>N = 5</td>
<td>87–95</td>
<td>–</td>
<td>&lt; 1 year</td>
<td>–</td>
<td>[16, 177]</td>
</tr>
<tr>
<td>ASYMAD</td>
<td>N = 13</td>
<td>75.9</td>
<td>≤ 0.5</td>
<td>28.3 ± 1.1</td>
<td>≈ 11 weeks</td>
<td>[17]</td>
</tr>
<tr>
<td>ASYMAD</td>
<td>N = 5</td>
<td>91–96</td>
<td>–</td>
<td>28–30</td>
<td>–</td>
<td>[18]</td>
</tr>
<tr>
<td>p-preAD</td>
<td>N = 13 + 20</td>
<td>53–88</td>
<td>0–3</td>
<td>28.3 ± 1.1</td>
<td>≈ 11 weeks</td>
<td>[19]</td>
</tr>
<tr>
<td>SMCpos</td>
<td>N = 88</td>
<td>70–85</td>
<td>0</td>
<td>27</td>
<td>–</td>
<td>[20]</td>
</tr>
<tr>
<td>SA</td>
<td>N = 172</td>
<td>&gt; 60</td>
<td>–</td>
<td>&gt; 24</td>
<td>–</td>
<td>[176]</td>
</tr>
<tr>
<td>High or intermediate likelihood</td>
<td>N = 48</td>
<td>28.2</td>
<td>–</td>
<td>23.93</td>
<td>1.18 year</td>
<td>[185]</td>
</tr>
<tr>
<td>Nondemented, meets AD criteria</td>
<td>N = 14</td>
<td>87.62</td>
<td>± 0.5</td>
<td>28.3</td>
<td>–</td>
<td>[209]</td>
</tr>
<tr>
<td>NDAN</td>
<td>N = 10</td>
<td>89.5</td>
<td>28</td>
<td>–</td>
<td>–</td>
<td>[230]</td>
</tr>
</tbody>
</table>

MMSE, Mini-Mental State Exam; CDR, Clinical Dementia Rating; ND-HPC, non-demented high pathology controls; ASYMAD, Asymptomatic AD; NDAN, non-demented individuals with AD neuropathology; p-preAD, pathologically diagnosed preclinical AD; SA, SuperAgers; SMCpos, amyloid-PET positive subjective memory complaint seniors.
exceptions with high scores (2 and 3) that were observed in two 'pathologically diagnosed preclinical AD' subjects, specifically a subject with argyrophilic grain disease, another type of dementia and a subject with both corticobasal degeneration and vascular dementia [79].

As an alternative for the CDR scoring, there is the MMSE, a questionnaire to measure cognitive impairment [192]. This test is divided into categories to test the functioning of time and spatial orientation, language, memory, repetition, and attention, resulting in a MMSE score indicating either normal cognition (score 24–30), mild (score 19–23), moderate (score 10–18), or severe cognitive impairment (score ≤ 9). Again, the cognitive function of all non-demented individuals in the NDAN studies was identified with a MMSE score of at least 24, but mostly above 27 (Table 2), indicating strong cognitive functioning. Nevertheless, it is important to keep in mind that even a maximum MMSE score of 30 does not rule out the possibility of developing dementia, and the MMSE score might change over time. Especially in NDAN, it remains uncertain whether the presence of AD pathology in these cognitively high functioning elders will still eventually cause dementia had they lived longer. Furthermore, a time delay between the latest cognitive evaluation performed antemortem and the post-mortem analysis of brain tissue is inevitable, for most studies this time delay was less than 1 years (Table 2).

Cognitive “reserve” and level and/or duration of education

One hypothesis that provides an explanation for the dissociation between AD neuropathology and dementia is “reserve”. In 2012, Stern explained that there were two types of reserve: brain reserve and cognitive reserve [175]. Brain reserve refers to physical differences in the brain that could advance tolerability against disease pathology (see the section NDAN on an organ level below). Additionally, cognitive reserve refers to the ‘resistance’ to neuropathological damage. Several studies suggested that cognitive reserve might be involved in NDAN’s resistance to cognitive decline [194–198]. And another study suggested that a higher cognitive reserve enables individuals to elongate the maintenance of their cognitive skills and therefore persist longer in an asymptomatic state [199]. It is hypothesized that individuals with AD pathology that initially performed cognitively well, will eventually develop MCI or AD, regardless of cognitive reserve.

Cognitive reserve refers to flexibility and efficiency in executing tasks and often clusters literacy, IQ, reading, virtue in social networks, lifestyle, and potentially most important, education. Already in 1990, Katzman et al. reported that lower education was indicative for a higher AD prevalence [200]. The Rotterdam Study confirmed these results, as they found as well that an increased risk of AD was associated with a lower educational level [201]. Additionally, a meta-analysis suggested that for every year increase in education, the prevalence of dementia was diminished by 7% [202]. Hence, it could conceivably be hypothesized that NDAN individuals attained a higher education level than AD individuals. In line with this hypothesis, Iacono et al. (2015) investigated the level of education of subjects from the Nun Study [18]. These authors found a significantly higher level of education (Masters or higher) in NDAN cases (61.5%), compared to both MCI (33.3%) and AD (29.3%) subjects. Similarly, in SuperAgers, cognitive reserve was suggested to be mainly developed over years of education [203]. Moreover, this link between level of education and dementia was thought to be caused by the putative unhealthy lifestyles of lower educated individuals. In an attempt to evaluate this hypothesis, Ngandu et al. (2007) demonstrated that unhealthy lifestyles may only independently contribute to reduction of cognitive reserve, not contribute to increased prevalence of AD itself [204]. With respect to the mechanisms underlying education and cognitive function in AD, researchers proposed that this was only associated with amyloid, not NFT [205]. To conclude, considering all this evidence it seems that NDAN individuals generally attended a higher educational level and/or were educated for a longer time, resulting in an increased cognitive reserve.

So higher educated individuals seem to have a greater reserve. However, when individuals with a higher IQ do decline, the terminal cognitive decline is much steeper compared to individuals with a lower IQ, as was concluded by investigating the rate and acceleration of cognitive decline in the final years of disease prior to death [206]. Additionally, another recently published study, which did not specifically look at IQ, but that investigated person-specific cognitive trajectories, also found that terminal decline contributes on average for about 70% to late-life
cognitive loss in the investigated cohort [207]. Interestingly, accelerated cognitive decline was also observed in a recent study in individuals who lost their home during the 2011 earthquake in Japan [208]. Even though there was quite some heterogeneity between individuals, the individuals that seemed most vulnerable to post-disaster accelerated cognitive decline tended to be less educated, as well as older, unmarried, not working, living alone, and had also baseline health problems [208].

All these studies provide insights, from different perspectives, into the process of resilience to cognitive impairment.

NDAN on an organ level

As was mentioned before, AD is characterized by neuronal atrophy in various regions of the brain (see the section on AD on an organ level). Various subtypes of AD have been described in this section, including cognitively impaired individuals without any hippocampal or cortical atrophy [90]. A possible explanation for these subtypes may be the lack of adequate knowledge in the pathology, one link that is repeatedly observed in NDAN. Are NDAN brains resilient to AD pathology or do they also encounter atrophy?

Hippocampal volume

The volume of the hippocampus is an independent criterion to distinguish between healthy and AD individuals. In one of the investigations from the Nun Study, they found that AD neuropathology was associated with a reduction of the hippocampal volume and that the brains of NDAN individuals did show hippocampal atrophy [209]. In contrast to Gosch et al. (2002), others reported that the volume of both the total brain and hippocampus were elevated in cognitively normal individuals with high AD neuropathology, compared to AD [210, 211]. Furthermore, in baseline measurements of SuperAgers (80+-year-old NDAN group), hippocampal volumes were found to be significantly larger compared to the normal aging controls [176]. These opposing findings suggest that brain and hippocampal volume by itself cannot explain the clinical-pathologic correlation in NDAN.

The genome-wide associated study performed by Guo et al. (2019) associated three small nucleotide polymorphisms in the TOMM40-APOC1 region, located on chromosome 19q13.32, with hippocampal atrophy and cognitive decline in non-demented older adults [212], indicating that genetic background affects hippocampal atrophy. Furthermore, another study indicated that hippocampal atrophy in AD is associated with vascular damage [213]. So far, however, it remains unknown whether the hippocampal and brain atrophy would be directly caused by NFT and Aβ plaques, since NDAN individuals do not necessarily show reduced hippocampal volume and/or brain atrophy despite their AD pathology.

Collectively, in NDAN, multiple studies indicate hippocampal volume changes while one study does not. As far as neurodegeneration is concerned, the most important factor remains age. One study did consider age in their analysis and reported that similar rates of atrophy were observed in both control and Aβ-resilient cases [14], suggesting that larger hippocampal volume could contribute to resilience to AD, but that structural decline eventually does occur over time.

Brain area dependency

Next to cognitive reserve (see the section on NDAN on a body level) resiliency to cognitive decline in NDAN could result from brain reserve [174, 175, 214]. Brain reserve refers to the ability to endure age-related changes and pathological damage, without developing symptoms. As mentioned above, the hippocampal volume is one of the mechanisms in brain reserve. Moreover, other structural changes or differences in the brain might be involved in the coping mechanism in NDAN individuals. Research from the AIBL study of Aging group (Table 1) used ¹¹C-PiB PET and MRI brain scans to investigate Aβ deposition in typical AD and NDAN subjects [215]. The authors found a greater temporal grey matter volume in ‘high-PiB healthy controls’, compared to ‘low-PiB healthy controls’. In other words, brain scans of NDAN subjects with high Aβ load showed a larger grey matter volume than healthy controls without Aβ in the temporal lobe.

Typically in AD, the hippocampus, particularly CA1 region, and entorhinal cortex are the first regions that are affected [73]. Afterwards, other parts of the temporal and parietal lobes and some of the frontal cortex and cingulate gyrus are affected. Surprisingly, in the 80+-year-old NDAN group, SuperAgers, a significantly thicker left anterior cingulate gyrus was found in comparison to both other 80+-year-olds and middle-aged controls [216]. Later these findings were confirmed by Gefen et al. (2015) who further reported that this region contains a lower NFT density in SuperAgers compared to other groups [177].
Moreover, they discovered a remarkably high presence of specialized nerve cells in the SuperAgers’ cingulate cortex: ‘von Economo-neurons’ (VEN). These neurons might be important to understand NDAN and will be discussed in the section NDAN on a cellular level. In the BLSA Study, the rCBF, a measure for local neuronal activity, was measured longitudinally up to 10 years prior to death by PET scan of ‘ASYMAD’ individuals, NDAN, and compared to cognitively impaired and cognitively normal older subjects [17]. Their analysis demonstrated that both the NDAN and the cognitively impaired group show similar rCBF declines in the precuneus and mesial temporal cortex over time. These results are consistent with observations seen in subjects with MCI, reflecting the stage before this decline further progresses into AD and before the thalamic regions are affected [94, 217]. Interestingly, only in the NDAN group, not in the cognitively normal, nor in the cognitively impaired group, an increase in rCBF could be observed in the hippocampus, parahippocampal gyrus, and anterior insula over time [17]. Despite the limited sample size in this BLSA study, it can be hypothesized that the resilience observed in NDAN individuals could be mostly contributed to the hippocampal area, the main affected area by AD.

**NDAN on a cellular level**

**Neurons**

As was briefly introduced in the previous section, the brains of the group SuperAgers contain a thicker region of the anterior cingulate cortex, which correlated with a higher density of the neuronal subtype VENs [177]. More precisely, Gefen et al. (2015) reported that the VEN density in SuperAgers was approximately 3- to 5-fold higher than in elderly control. VENs are rare, spindle neurons, that are characterized as slim, bipolar neurons located in the anterior cingulate cortex and fronto-insular cortex, and named after Constantin von Economo who first described them [218, 219]. Loss of VENs is associated with frontotemporal dementia, a type of dementia with atrophy in the anterior cingulate cortex early in its progression, resulting in aberrant social behavior [220]. However, the function of these spindle neurons has not yet been completely clarified. Gefen et al. (2018) found no significant association between the density of VENs and Braak stages [16]. However, in the same study, lower VEN density was observed in AD and in amnestic MCI cases, compared to elderly controls. Moreover, they demonstrated the highest density of VENs in SuperAgers, even in comparison with young adults, which was consistent with their previous findings [177]. It would be interesting to investigate whether VENs remain retentive in brains of other NDAN subpopulations.

Neuronal hypertrophy is a hypothesized compensatory mechanism that prevents AD progression. Hypertrophy refers to an increase in size, in this case of neural cells. Studies performed by Iacono et al. reported significant hypertrophy of neuronal cell bodies, nuclei, and nucleoli in NDAN individuals, particularly in the CA1 region of the hippocampus and the anterior cingulate gyrus [197, 221]. This observation was in agreement with findings of the BLSA study, in which neuronal hypertrophy was proposed as a compensatory mechanism for atrophy that prevents AD pathology [222].

As discussed earlier in this review, adult hippocampal neurogenesis is reduced in AD and MCI brains. Moreover, an interesting working hypothesis could be that neurogenesis is preserved in NDAN individuals. In agreement with this hypothesis, a recent study found an elevated amount of NSCs and newly matured neurons in NDAN individuals [9]. Postmortem miRNA analysis of the dentate gyrus in the hippocampi of NDAN revealed that NDAN expressed lower levels of miRNAs known to regulate neurogenesis (miR-9, miR-25, miR-29a, miR-124, miR-132, miR-137) compared to controls, MCI, and AD [9]. Moreover, in the dentate gyrus, immunofluorescence studies for SOX2, a transcription factor crucial for maintenance of neuronal stem cells, also showed a higher amount of SOX2 positive NSCs, compared to AD and MCI controls. Interestingly, a positive correlation was found between the fraction of SOX2 positive cells and cognitive functioning prior to death. Taken together, these findings indicate a role of neurogenesis as a possible mechanism allowing for the resistance of AD pathology [9]. In another study, NSC culture-derived exosomes were investigated for their function in neurogenesis [223]. Exosomes are nano-sized extracellular vesicles, that contain information (e.g., lipids, proteins, RNAs, genetic material) about the cells that secrete them [224]. Moreover, these vesicles have been reported to spread pathological proteins and lipids involved in AD [225]. To investigate whether exosomes originating from neuronal stem cells can prevent synaptic loss and memory impairment, Micci et al., 2019 cultured adult rat hippocampus NSCs and injected their exosomes intracerebroventricularly in healthy mice, and found that the NSC-secreted exosomes showed reduction

1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228
in Aβ oligomer-binding to synapses, and neutralize memory deficits caused by Aβ oligomers [223]. Surprisingly, exosomes originating from mature neuronal hippocampal cell culture did not show these effects, highlighting the importance of NSCs and neurogenesis. miRNA analysis of the exosomes originating from both cell cultures showed an enrichment of miR-485, miR-322, and miR-17 in NSC-derived exosomes. The use of miRNA mimics further validated the role of miR-17 and miR-485 in protecting synapses from Aβ oligomer-binding [223].

The key implication to draw from these two studies is that neurogenesis seems to be preserved in NDAN individuals, resulting from increased levels of hippocampal NSCs, with elevated SOX2 expression and these NSC may secrete exosomes, transporting particular miRNAs that protect synapses against Aβ oligomers. In the following section, other mechanisms will be discussed that prevent Aβ oligomeric toxicity in synapses and preserve cognitive functioning in NDAN individuals.

Taken together, it seems that specialized neurons in the hippocampus, VENs and NSCs, are particularly upregulated in NDAN individuals. This resistance could be parallel to or causal to hippocampal hyperrophy that would increase brain “reserve” in NDAN individuals.

**Immune cells**

As was pointed out earlier (see the section AD on a cellular level), the important contribution of neuroinflammation in the pathology of AD is becoming more and more acknowledged. Already in the early stages of AD, neuroinflammatory responses are very diverse between individuals [112]. Interestingly, it is believed that inflammation during the early stages of AD contributes to the development of AD and cognitive impairment later in life [112]. Considering NDAN, it could be that inflammation is decreased and therefore inhibits progression of dementia. This could be attributed to the microglial phenotype, M1 and M2, and the ratio in which they have proliferated in the brain after detection of Aβ or tau protein aggregates. Hence, it could be hypothesized that in NDAN the AD pathology does not result in proliferation of, and differentiation into the M1 microglia, but in M2 microglia, showing a stronger phenotype of classic inflammation inhibition. To best of our knowledge to date, however, no single study exists that discriminates between the different microglial phenotypes in NDAN.

The study by Melah et al. (2016) showed that neuroinflammation aggravates neural damage, as they found a correlation between the neuroinflammatory markers, YKL-40 and MCP1, and the neural damage markers, NFL and tau levels, in the CSF in asymptomatic adults with AD pathology carrying the risk gene APOE e4 [226]. However, they did not specifically look at microglia. In another study, microglial activation was evaluated in brains of SuperAgers, to investigate the response to age-related pathology [227]. Older adults in this study showed increased microglial density in white matter regions that correlate with the affected regions in AD as described in the section AD on an organ level. On the other hand, this increased microglial density was not observed in SuperAgers, giving us another interesting possible explanation for the high cognitive functioning in these individuals. These results match those observed in the study of Perez-Nievas et al. (2013), who found a significantly lower amount of microglia, and also of astrocytes, in the superior temporal sulcus of their NDAN group [13]. In this study, the NDAN group was divided into high probability (HP, Braak stage V-VI) to develop AD and intermediate probability (IP, Braak stage III-IV) to develop AD. The lower levels of glial activation in these HP and IP resilient cases indicate that neuroinflammation might be suppressed in NDAN but does not address further mechanistic insights.

A follow-up study performed by the same research group of Perez-Nievas investigated neuroinflammation in NDAN individuals by quantifying cytokines in brain tissue [178]. Using a multiplex immunoassay, increased expression of neurotrophic factors was found in both HP and IP resilient cases, compared to AD cases. Neurotropic factors are beneficial for NDAN cases, since they support neuronal growth, differentiation, and survival [228]. Moreover, both HP and IP resilient cases show upregulated cytokines in the entorhinal cortex, compared to AD cases [178]. Interestingly, in the HP cases IL-1β, IL-6, IL-13, and IL-4 were found to be upregulated, while IL-6 and IL-10 were found to be upregulated in the IP resilient cases. This brings back the hypothesis stated at the beginning of this section, namely that toxicity of AD pathology might depend on the balance between the classic pro-inflammatory M1 microglia population relative to the alternative anti-inflammatory, wound healing M2 microglia population, as classic activation of microglia (M1) is mainly mediated through TNF-α, IL-1, IL-12, IL-23, and interferon-γ, whereas alternative (M2) microglia...
activation primarily through transforming growth factor-β, IL-4, IL-10, and IL-13 [118, 119]. This combination of findings supports the hypothesis that AD pathology in NDAN results predominantly in activation of the anti-inflammatory M2 microglia and so suppresses neuroinflammation. However, further research is required to investigate the microglial phenotypes during neuroinflammation in NDAN cases.

Collectively, these studies indicate that neuroinflammation is reduced in NDAN cases, as a result of decreased glial density. Furthermore, the different cytokine profiles suggest the hypothetical anti-inflammatory phenotype of microglia.

**NDAN on a biochemical level**

Multiple mechanism underlying NDAN resistance to AD have already been discussed on an organism, organ, and cellular level. For this section, several biochemical mechanisms will be discussed as potential mechanisms that could explain the resilience to AD in NDAN individuals.

**Amyloid-β pathology**

One key player in the neuropathology of AD is Aβ. Unfortunately, the amount of amyloid plaques used to identify NDAN individuals differs per author, as is reflected in the different CERAD scores, a semi-quantitative measure for neuritic amyloid plaques, in Table 3. Most of these studies investigated NDAN cases around the same age and all have a limited number of subjects. For most articles, only a high CERAD rating was confirmed even though some other articles include CERAD scores lower than moderate.

Compared to young healthy adults, cognitively normal aging adults demonstrated increased fibrillar Aβ plaques in the temporal lobe and partially in the parietal region (particularly the precuneus), as visualized by PET using PiB staining [44]. Moreover, tau and Aβ changes in CSF can occur approximately 15 years prior to the clinical onset of AD [229]. Together, these studies highlight that brains of preclinical AD and of normal aging both contain Aβ pathology, which makes it difficult to diagnose AD. Further complicating AD diagnoses are the individuals that remain non-demented, despite the presence of Aβ aggregates in their elderly brain, the individuals we refer to in this paper as NDANs [63, 71, 186–190]. Interestingly, the study by Bjorklund et al. (2012) showed that the levels of Aβ plaques, tau tangles, Aβ42, and low molecular weight Aβ oligomeric species in brains of NDAN were comparable to the levels in AD brains [230]. Despite the similar levels of Aβ species in both AD and NDAN brains, Aβ oligomers did not bind the synapses nor affected the post-synaptic density. Interestingly, using immunohistochemistry and conformation-specific antibodies that recognized Aβ oligomer deposits (NAB61), Perez-Nievas et al. (2013) observed a significant decrease in the load of Aβ oligomeric deposits, in the group they termed ‘high probability mismatches’.

**Table 3**

Selected studies on classification of non-demented individuals with AD neuropathology on Braak staging to classify the degree of NFT, and CERAD rating to measure the amyloid plaques

<table>
<thead>
<tr>
<th>Synonym</th>
<th>Number of participants</th>
<th>Age (years)</th>
<th>Braak stage</th>
<th>CERAD rating</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDAN</td>
<td>N = 4</td>
<td>&gt; 89</td>
<td>IV–VI</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>NDAN</td>
<td>N = 8</td>
<td>76–89</td>
<td>IV–VI</td>
<td>–</td>
<td>[10]</td>
</tr>
<tr>
<td>HP</td>
<td>N = 8</td>
<td>88.4</td>
<td>V–VI</td>
<td>Frequent</td>
<td>[13]</td>
</tr>
<tr>
<td>IP</td>
<td>N = 12</td>
<td>≈ 89.82</td>
<td>III–IV</td>
<td>Moderate</td>
<td>[13]</td>
</tr>
<tr>
<td>SA</td>
<td>N = 5</td>
<td>87–95</td>
<td>0–III</td>
<td>–</td>
<td>[16, 177]</td>
</tr>
<tr>
<td>ASYMAD</td>
<td>N = 6</td>
<td>&gt; 75.9</td>
<td>II–IV</td>
<td>Moderate</td>
<td>[17]</td>
</tr>
<tr>
<td>ASYMAD</td>
<td>N = 13</td>
<td>≈ 89</td>
<td>I–III</td>
<td>76.9 % – Moderate</td>
<td>23.0 % – Frequent</td>
</tr>
<tr>
<td>AsymAD</td>
<td>N = 33</td>
<td>79–96</td>
<td>I–IV</td>
<td>–</td>
<td>[19]</td>
</tr>
<tr>
<td>ASYMAD</td>
<td>N = 15</td>
<td>71–96</td>
<td>II–IV</td>
<td>Moderate – frequent</td>
<td>[21]</td>
</tr>
<tr>
<td>p-preAD</td>
<td>N = 13 + 20</td>
<td>53–88</td>
<td>I–III</td>
<td>None – sparse</td>
<td>[79]</td>
</tr>
<tr>
<td>HP</td>
<td>N = 12</td>
<td>≈ 86.1</td>
<td>V–VI</td>
<td>Moderate – frequent</td>
<td>[178]</td>
</tr>
<tr>
<td>IP</td>
<td>N = 21</td>
<td>≈ 86.6</td>
<td>III–IV</td>
<td>Sparse – frequent</td>
<td>[178]</td>
</tr>
<tr>
<td>AsymAD</td>
<td>N = 21</td>
<td>≈ 75.59</td>
<td>≥ II</td>
<td>Moderate – frequent</td>
<td>[190]</td>
</tr>
<tr>
<td>NDAN</td>
<td>N = 10</td>
<td>≈ 89.5</td>
<td>IV–VI</td>
<td>Moderate</td>
<td>[230]</td>
</tr>
<tr>
<td>NDAD</td>
<td>N = 10</td>
<td>86.6 ± 5.3</td>
<td>II–IV</td>
<td>Moderate–frequent</td>
<td>[237]</td>
</tr>
</tbody>
</table>

CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; ASYMAD, Asymptomatic AD; NDAD, non-demented individuals demonstrating intermediate AD neuropathologies; ND-HPC, non-demented high pathology controls; NDAN, non-demented individuals with AD neuropathology; HP, high probability; IP, intermediate probability; p-preAD, pathologically diagnosed preclinical AD; SA, SuperAgers.
NDAN, compared to AD patients [13]. These observations imply that the levels of soluble Aβ species in NDAN are comparable to those in AD, but that Aβ oligomers are less deposited in NDAN. These findings were supported by Bilousova et al. (2016), who found higher levels of soluble oligomeric Aβ surviving within synaptic terminals in demented cases, but not in NDAN [231]. Furthermore, the study of Bjorklund et al. (2012) found that in contrast to AD cases, NDAN individuals did not show Aβ oligomers in the hippocampal postsynapses, even though the Aβ oligomers were present in the ‘soluble fraction’ of the synaptic fractionation performed on the hippocampal tissue [230]. This observation is crucial because it suggests that Aβ oligomeric binding to synapses is needed to maneuver AD pathology into dementia and furthermore suggests a potential safety mechanism in NDAN that prevent binding to synapses. Interestingly, in line with this hypothesis, the same study showed that while the hippocampi of AD cases contained elevated synaptic Zn$^{2+}$ levels, both in the ‘soluble fraction’ and the synaptic vesicles, NDAN cases only showed elevated levels of Zn$^{2+}$ at the synaptic vesicles [230]. These findings correlated with regular expression of the synaptic Zn$^{2+}$ transporter ZnT3, which was impaired in the AD cases [230]. These findings indicate that NDAN cases can better maintain synaptic Zn$^{2+}$ homeostasis and thereby regulate synaptic binding of Aβ oligomers. This understanding is crucial because it could lead to new therapeutic insights to prevent AD.

As discussed in the section AD on a biochemical level, amyloid-β pathology, soluble Aβ oligomers induce synaptic damage thereby leading to inhibition of long-term potentiation [148]. Interestingly, the neuromodulator Reelin has been suggested to have an Aβ-antagonist-like function at the synapses [232]. Typically, Reelin contributes to the regulation of neuronal migration in the brain development by controlling cell-cell interactions mediated by binding to the postsynaptic APOE receptors VLDLR and APOER2. By binding to VLDLR and APOER2, Reelin is thought to counteract Aβ-induced synaptic suppression [233]. Interestingly, also elevated levels of Reelin were observed in the hippocampal pyramidal neurons of NDAN individuals [233], suggesting a potential compensatory mechanism. However, Reelin was also upregulated in the cortex and CSF of patients with AD [234], and it has been proposed that elevated levels of Reelin do not necessarily contribute to, or are not sufficient for, the resistance of AD pathology [234], but this might depend on other unknown factors.

Interestingly, insulin signaling also seems to fulfill an Aβ-antagonist-like function. Using primary neuronal cell culture models, De Felice et al. (2009) observed that soluble Aβ oligomers induced downregulation of the insulin receptor at the plasma membrane [235]. In fact, adding insulin itself prevented not only binding of soluble Aβ oligomers to the synapses and downregulation of the insulin receptor, but was also able to abolish Aβ-induced oxidative stress and able to prevent Aβ-mediated synapse loss [235]. Interestingly, the protective role of insulin dependent on the kinase activity of the receptor, indicating that insulin signaling is responsible for the protective effect. In a review paper, Taglialetela reported unpublished data on decreased signaling components of the insulin transduction pathway in AD hippocampi compared to controls and NDAN [181]. Furthermore, in the hippocampus of NDAN individuals an even higher pathway activation was observed compared to AD and controls cases [181]. Overall, this suggests that maintenance of the insulin signaling pathway contributes to the preservation of synapses and cognitive integrity.

As described before in the context of neurons in NDAN, NSC-secreted exosomes were able to prevent synaptic degradation through upregulation of specific miRNAs [223]. In line with this finding, the synaptic miRNA expression was investigated in hippocampal tissue of NDAN subjects [182]. Specifically, they identified three miRNAs, miRNA-485, miRNA-4723, and miRNA-149, to be differently expressed in hippocampal tissue of NDAN and AD, compared to controls [182]. All three miRNAs regulate the protein expression of synaptic genes, such as APP and β-secretase 1, and intracerebroventricularly administration to adult wild-type mice resulted in increased synaptic resilience to Aβ oligomers [182]. While a very interesting discovery, focus lied on upregulation of these miRNAs, knockdown studies in cell culture systems and/or animals would provide crucial insights whether the disruption of these miRNAs will lead to or enhance Aβ-toxicity.

Overall, it seems that Aβ oligomers bind to synapses, thereby resulting in synaptic dysfunction in AD. Various observations in NDAN individuals together gave insights on potential mechanisms preventing Aβ-mediated synapse loss: better maintained Zn$^{2+}$ homeostasis, upregulation of Reelin, increased levels of insulin signaling components, and miRNAs that regulate the protein expression of...
**APP and β-secretase genes in synapses.** However, as these findings were done independently of each other, it remains unclear whether they act independently or parallel to each other or even synergistically, and further research is required to understand the full, coherent picture that explains the role of Aβ oligomer binding to preserve cognition and prevent dementia.

**Tau pathology**

The other key player in the neuropathology of AD is aggregation of the protein tau. Similar to Aβ aggregation, tau aggregation can also be observed in normal aging (section on Normal aging). One of the biochemical mechanisms that could potentially be underlying NDAN resistance to AD pathology is the inhibition of NFT formation resulting from for instance changes in tau isoform expression, as well as changes in activities of tau kinases and phosphatases. One study investigated tau isoforms in brain areas affected and unaffected by NFT, in both AD and control using RT-PCR and they showed that the relative expression of tau isoform 0N3R was higher in the affected temporal cortex than in the unaffected cerebellar cortex, in both AD and control [236]. It would be interesting to investigate the tau isoform expression in NDAN to provide more inside into the NFT formation in NDAN. As was pointed out in the section “normal” aging, tau deposition is generally observed in older adults [44]. This study shows that for *in vivo* Braak staging, there is a higher within-group variance for cognitively intact elderly, than for young adults and AD patients. This within-group variance could therefore also be observed for NDAN cases. Moreover, between authors, different approaches are used for both Braak stages to identify NDAN cases (Table 3).

So certain amounts of tau species have been found in NDAN brains. What is not yet clear is what type of tau species were found (see also Supplementary Figures 1 and 2), and whether these would differ from the type of tau species found in AD. Perez-Nieves et al. (2013) investigated what tau species could contribute to the resilient mechanism in NDAN, particularly soluble tau versus NFT [13]. In their results, mostly tau monomers were found in controls and NDAN. Compared to healthy controls, only AD cases had an abnormal accumulation of soluble mono- and multimeric species of hyperphosphorylated tau in the synapses, not the high probability mismatch cases [13]. In other words, the accumulation of soluble hyperphosphorylated tau in synapses seems more manageable in NDAN-brains, compared to AD.

Another study investigated the correlation between Braak’s staging system and intact cognitive outcome, using MMSE scores, with data from the Nun Study and the National Alzheimer’s Coordinating Center [12, 193, 197]. This data showed that the cognition of individuals with Braak stages V and VI were significantly different from each other. Therefore it was stated in this paper that these two Braak stages should not be combined in the determination of NDAN individuals [193]. Moreover, there were no cognitive intact individuals found with the highest Braak stage in this study. Therefore, it is necessary to form concrete inclusion criteria to categorize NDAN individuals.

**Gene expression**

Gene variants and changes in gene expression in NDAN brains can provide insight into the upstream mechanism underlying dementia. Liang et al. (2010) performed postmortem transcriptomics analysis on 6 different brain regions comparing AD individuals, NDAN individuals, and healthy elderly controls [237]. They found that, while both NDAD and AD brains showed similar expression changes in tangle- and plaque related pathways and ubiquitin-proteasomal pathways, NDAN individuals displayed unique expression changes in most brain regions in genes correlating with learning and/or memory processes. More specifically, they found a downregulation several genes, including *APOE*, while genes such as *MAPT* and ephrin-B2, involved in cell signaling and mediating neural development, were upregulated [237]. These finding suggest that the transcriptomic changes may represent compensatory mechanisms against cognitive decline. This study stresses the importance of transcriptomic in the quest to unravel underlying mechanisms, focusing on expression of notorious AD-related genes. Nevertheless, recently a study was conducted suggesting another potential component that reduces the risk for AD and other types of dementia. In this study, a genetic variant in the phospholipase Cy2 (*PLCG2*) gene was suggested to reduce AD risk [238]. The *PLCG2* gene was found to have a role in immune system signaling, suggesting a protective effect against neurodegenerative diseases, including AD. The authors in this study indicate that the genetic variant of this gene is associated with an increased longevity and reduced AD risk [238]. It is therefore
not unlikely that a connection exists between this genetic variant and NDAN.

**DISCUSSION AND CONCLUSIONS**

The aim of this review was to achieve more insight into the mechanism underlying NDAN resistance to dementia. Thus far, we have evaluated various mechanisms on a body, organ, cellular, and biochemical level based on a large variety of studies. All the included studies in this review were based on cognitively normal elderly, defined as a MMSE score > 24, and with age 60 years or older, carrying the AD pathology (Table 2). So far in literature, there has not been a concrete definition for NDAN-like individuals, and it can be debated which MMSE cut-off score best reflects cognitively intact elderly. Similarly, the degree of AD pathology in literature, as summarized in Table 3, is inconsistent. Therefore, for future studies, clarity is needed to form concrete inclusion criteria for NDAN, for which Tables 2 and 3 can be used to form an overview.

Key findings that could partly explain why this small group of NDAN individuals, which carry AD pathology but stay cognitively intact, are summarized here. Generally, NDAN individuals have attended higher education, than individuals with MCI or AD, and therefore may possibly have a higher cognitive reserve. Secondly, researchers debate on the relationship between hippocampal volume and NDAN resilience to dementia. However, most of the studies indicate that hippocampal atrophy is compensated for in NDAN, which could result from increased neuronal hypertrophy in NDAN’s hippocampal neurons. Moreover, the cingulate gyrus was found to be thicker and overall the grey volume was larger in NDAN, compared to AD cases. Besides neuronal hypertrophy, two different studies each looking at only one specific cell-type found an elevated presence of specialized neurons, such as VENs and NSCs, in NDAN individuals. Furthermore, adult neurogenesis seems to be preserved in NDAN individuals, which can be attributed to increased levels of hippocampal NSCs and their elevated SOX2-expression allowing for stem-cell renewal. Thirdly, neuroinflammation is suppressed in NDAN as associated with decreased glial activation. Moreover, compared to AD cases, the cytokine signature in NDAN individuals represented more an anti-inflammatory state, with elevated levels IL-4 and IL-13, further thus supporting the hypothesis that neuroinflammation is decreased in NDAN cases. Lastly, looking at the AD hallmarks Aβ and tau pathology, NDAN cases have more tau monomers and less accumulation of soluble hyperphosphorylated tau at the synapses, but further research is needed, including elucidation of the different tau species and their distribution in NDAN cases compared to control and AD cases. Looking at the Aβ pathology, in NDAN several biochemical mechanisms for synaptic resilience to Aβ-oligomeric binding have been suggested, namely preserved synaptic Zn2⁺ homeostasis, better maintenance of the insulin signaling pathway and increased expression of three miRNAs involved in the regulation of expression of synaptic genes.

Altogether, these different mechanisms discussed in this review shed new light into the underlying mechanism of NDAN cases, “normal” aging, and AD (Fig. 2). It is clear that despite the growing literature regarding NDAN, additional studies will be needed to develop a better picture of NDAN to disentangle NDAN cases from “normal” aging and AD and to gain insights into possible drug targets for AD. Regarding resilience to AD pathology on an organ level, NDAN researchers have been focused primarily on the hippocampus, while cortical regions that are affected in AD, are not taken into account in most investigations in NDAN individuals. Moreover, literature regarding hippocampal volume in NDAN cases show contradicting findings, suggesting that further research is required. Furthermore, other circumstances, including time and aging, that could affect the hippocampal volume and neurogenic factors will provide further crucial insights. Based on the cytokines profiles of NDAN cases, we hypothesized that NDAN individuals display a different ratio of M1 and M2 microglial phenotypes, specifically we hypothesized that in NDAN, classic inflammation is inhibited by M2-microglial cells for which Tables 2 and 3 can be used to form an overview.

Looking at the Aβ toxicity, the observation that Aβ-oligomeric binding to synapses is reduced in NDAN, brings new insights into the development of novel therapeutic approaches aiming to improve synaptic resistance to Aβ oligomeric toxicity. Regarding the other AD hallmark, tau, the mechanisms involved in NDAN have to be investigated more extensively, therefore it was proposed to investigate what type of tau species was found in NDAN brain, compared to normal aging and AD, and where it distributed to. What was already found in literature is that NFT formation in the temporal cortex was inhibited, due to lower 0N3R expression.
Various observations in NDAN individuals have tried to provide an explanation how Aβ-synapse binding is mediated: Zn\(^{2+}\) homeostasis, the extra-cellular matrix protein Reelin, insulin signaling, and miRNAs that regulate APP and β-secretase expression levels in synapses. Unfortunately, these are all different mechanisms studied independently, and a more comprehensive and holistic study looking at these mechanisms all in the same individual, to the best of our knowledge, so far has been lacking. Further a holistic research approach is required to form a coherent entity that explains the role of Aβ oligomer binding to preserve cognition and prevent dementia. The observation that neurogenesis is more pronounced in NDAN individuals than in AD, also provides and interesting therapeutic potential, for instance focused on NSC proliferation in the hippocampus.

Similar to the longitudinal cohort studies that have been performed in America and Australia, among others, more recently, researchers in The Netherlands launched two cohort studies to investigate several types of diseases in elderly [239, 240]. They both investigated the increasing prevalence of dementia with age and investigated the impact of lifestyle factors on AD. However, they did not yet study or publish whether a group of NDAN would exist in this cohort, for the potential reason that they did not yet performed autopsies in this study. Nevertheless, it would be interesting to see also the NDAN individuals in these cohorts.

A major limitation of the field, and thereby as well of this review, is that most research groups use their own synonym to refer to non-demented elderly with AD pathology. Not only do different studies use different synonyms, but also use different measurements and thresholds to classify these subjects. While some studies expect that these subjects will eventually develop dementia, so study them as pre-clinical, other studies focused only on the individuals with really severe AD pathology. Another issue is the lack of awareness regarding the non-demented individuals in most AD studies. Despite the alterations made by the Alzheimer’s Association to separate the NDAN from AD cases, not all researchers considered NDAN in their study design. Also, we have to consider that NDAN individuals included in the studies generally attended higher education, suggesting that these individuals have already been cognitively stronger than the ones with lower education, creating educational bias. Then, the biggest question in NDAN is time, in particular the contribution of aging in the pathology of AD. In this review, both longitudinal and cross-sectional studies have been presented. In longitudinal studies (e.g., cohort studies), the same subjects are observed at multiple points in time, whereas cross-sectional studies take a snapshot by investigating a population at a fixed time point, for example, postmortem. Looking at the contribution of time in the presented studies, a limitation of postmortem brain analysis in cross-sectional studies is the absence of information on the subjects’ brain during life. The NDAN subjects in the studies described in this review had intermediate to high AD pathology in their brains. However, it could never be confirmed with certainty that these subjects would not eventually have developed dementia and a certain time delay between cognitive testing and death is inevitable. As discussed in the section NDAN on a body level, both Driscoll et al. (2006) and Dang et al. (2019) observed that cognitive functioning of their NDAN group declined over time, comparable to cognitively normal elderly [14, 190]. This suggests that despite their resilience to AD pathology, time remains one of the most important factors in the pathology. Hence, Goldberg (2019) reviews these SuperAger studies, suggesting that age needs to be considered more [241]. Moreover, he implied that SuperAgers are not necessarily superior, but rather “LuckyAgers”, questioning the resilience, cognitive reserve, and neurological changes in these individuals. From this perspective, aging itself seems one of the largest risks for neurodegenerative diseases, as confirmed by the Nun Study. On the other hand, some studies indicated the uniqueness of NDAN individuals, as being cognitively intact despite AD pathology [17, 61]. Especially Dubois et al. (2018), who launched a longitudinal study aiming to discover new insight into the compensation mechanism in cognitively intact individuals with AD pathology [172]. The last issue we would like to raise is that the current literature on NDAN-like individuals implemented their test group by different conditions, therefore comparing different studies could be unjustly or at least requires some caution. So far, no concrete inclusion criteria have been defined to categorize NDAN individuals.

Despite evidence on both sides, resilience to pathology or simply a preclinical indication, it is most important that the contribution of age to AD pathology is not forgotten in any NDAN research, as well as that we would consider NDAN subjects as a unique group that could provide crucial insights into compensation mechanisms in the prevention of dementia.
This review intended to form a broad overview into the different aspects that are involved in NDAN and compared these mechanisms to those in “normal” aging and AD itself. The suggestions given in this review lay the groundwork for future research into the mechanism that prevents clinical progression to dementia.

ACKNOWLEDGMENTS

We wish to express appreciation to Christiana van Leerdam for making all graphical figures that are present in this review.

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/21-0607r2).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: https://dx.doi.org/10.3233/JAD-210607.

REFERENCES

[23] Consumer Reports, Evaluating Prescription Drugs Used to Treat: Alzheimer’s Disease Comparing Effectiveness, Safety and Price, Last updated May 2012,


Lazarov O (2019) Human hippocampal neurogenesis persists in aged adults and Alzheimer’s disease patients HHS


